Translating biological insights into clinical endpoints in neuro-oncology

The Lancet Oncology

Volumn 10, Issue 10, 2009, Pages 928-929

  Bredel, Markus ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; VASCULOTROPIN;

ADJUVANT THERAPY; BLOOD BRAIN BARRIER; BRAIN EDEMA; BREAST CANCER; CANCER CELL DESTRUCTION; CLINICAL DECISION MAKING; CLINICAL TRIAL; COLON CANCER; DRUG COST; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TUMOR RECURRENCE; TUMOR REGRESSION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG APPROVAL; GLIOBLASTOMA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); UNITED STATES;

EID: 70349385649     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70192-5     Document Type: Letter

References (7)

1. Wen P.Y., and Kesari S. Malignant gliomas in adults. New Engl J Med 359 (2008) 492-507
2. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
3. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
4. Bredel M., Scholtens D.M., Harsh G.R., et al. A network model of a cooperative genetic landscape in brain tumors. JAMA 302 (2009) 261-275
5. Nghiemphu P.L., Liu W., Lee Y., et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72 (2009) 1217-1222
6. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (2006) 157-173
7. Yaziji H., Goldstein L.C., Barry T.S., et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 (2004) 1972-1977